Booklet Esmo - Emirates Oncology Society

Managed byFriday June 11th & Saturday June 12th | 2021

SCIENTIfiC PARTNER ENDORSED BY


MD(Hon), MRCP(UK), FRCP(C), FACPConsultant of OncologyPresident of Emirates Oncology SocietyDirector of Oncology Services - VPS HealthABIM Board Certified in Internal Medicine and Medical OncologyProfessor - University of Sharjah

Welcome Message

Prof. Humaid Al-Shamsi

Dear Colleagues,

On behalf of the Emirates Oncology Society, we would like to invite you, delegates, esteemed faculty, committees, industry partners and friends, once again to the Best of ESMO Breast Cancer - UAE 2021 Virtual Edition, scheduled to take place on Friday June 11th, and Saturday June 12th, 2021.

It is the drive to achieve the best level of oncology care that positions the Emirates Oncology Society once again on a pathway of scientific excellence in the UAE Best of ESMO Breast Cancer - UAE 2021 Virtual Edition set to bring the best topics on Breast Cancer from the international ESMO.

This event is brought to you in response to an exceptional level of interest from our friends and partners for the Emirates Oncology Society to add the Best of ESMO to the UAE Calendar of Oncology Events. We look forward to collaborating with you all to make this event another success story for the Society and to continue our journey towards reaching the highest standards of oncology care together.

With best regards,Dr Humaid Al Shamsi

Managed by


MDConsultant Medical Oncologist UAE

Dr. Aydah Al Awadhi

MD(Hon), MRCP(UK), FRCP(C), FACPConsultant of OncologyDirector of Oncology Services - VPS HealthProfessor - University of SharjahEOS President


MD, BCSenior Clinical OncologistDubai Hospital, UAE

Dr. Dina Hamza

MD, PhD, MRCP, MRCP (Med Onc), CCT, FRCPConsultant Medical Oncologist,Saudi German Hospital Dubai, UAEEOS General Secretary

Dr. Saeed Rafii

Scientific CommitteeManaged by

ModeratorsManaged by


MD, FRCPCAssistant Professor at King Saud Bin Abdulaziz University for Health Science – NGHA, KSASaudi Oncology Society President

Dr. Meteb Al-Foheidi

MDAdult Medical Oncology,King Abdulaziz Medical CityAssistant Professor, King Saud bin Abdulaziz University for Health Sciences, SA

Dr. Omalkhair Abulkhair

MDProf. of Clinical OncologyChairman of Kasr El Ainy Center,Cairo University, Egypt

Prof. Dr. Emad Hamada


FacultyManaged by

MDProfessor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Nuhad Ibrahim

MD, PhDAssociate Professor of Medical Oncology University of Milano, Italy

Prof. Giuseppe Curigliano

MDAssociate Professor of Gynecology and Obstetrics, Translational Medicine,University Hospital Erlangen, Germany

Dr. Peter Fasching

Dr. Sukhbinder Dhesy-Thind

MD, MSc, FRCP(C)Medical Oncologist at the Juravinski Cancer CentreAssociate Professor and Associate Chair (Education) in the Department of Oncology at McMaster University, Canada

MD, Professor of Oncology, Director of the Division of Medical Oncology 2 at the Padua IstitutoOncologico Veneto,University of Padova, Italy

Prof. Pierfranco Conte

MDMedical oncologist at the department of General Medical Oncology, University Hospitals Leuven, Belgium

Dr. Kevin Punie


FacultyManaged by

MDProfessor Clinical Oncology Cairo University, Managing Director of Cairo University Center of Oncology and Nuclear Medicine NEMROCK, EgyptPresident of CANSURVIVE

Prof. Mohsen Mokhtar

MD, Medical Oncologist, Freeman HospitalLead Clinician for Breast Cancer, Northern Cancer Alliance, UK

Dr. Mark Verrill

MD, PhD Head of Medical Oncology Clinic at Jules Bordet Cancer Institute Brussels, Belgium

Dr. Ahmad Awada

MDMedical Oncology ConsultantSheikh Khalifa Specialty HospitalRas Al Khaimah, UAE

Dr. Hassan JaafarMD, American Board-CertifiedConsultant Medical Oncologist & Consultant Clinical HematologistKing's College Hospital, UAE

Dr. Hassan Ghazal

PhD clinical oncologyAssistant professor clinical Oncology Senior Specialist Medical Oncology, Dubai Hospital, UAE

Dr. Dalia Elshourbagy

Dr. Maroun El Khoury

MDConsultant Hematologist/Oncologist at American Hospital, UAEChairman of Scientific Committee EOS


AgendaManaged by

Friday June 11th | 2021

CHAIRPERSON: DR. AYDAH AL-AWADHI │ DR. OMALKHAIR ABULKHAIR

07:30 PM - 07:40 PM Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: survival resutls of the UNICANCER-NeoPAL study

Dr. Nuhad Ibrahim

07:40 PM - 07:50 PM Pooled analysis of patient reported outcomes (PROs) in the MONALEESA (ML)-2, -3, and -7 trials: additional results and key subgroup findings

Dr. Nuhad Ibrahim

08:00 PM - 08:10 PM Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT) and interstitial lung disease (ILD) in monarchE

Dr. Peter Fasching

07:50 PM - 08:00 PM Atezolizumab with carboplatin as immune induction in metastatic lobular breast cancer: First results of the GELATO-trial

Dr. Peter Fasching

08:10 PM - 08:20 PM Progression a�er CDK 4/6i: How to sequence approved options Dr. Dalia Elshourbagy

08:20 PM - 08:30 PM PANEL DISCUSSION All

08:30 PM - 09:00 PM Navigating a new clinical reality in advanced breast cancer: Treatment considerations in the real world


UAE TIME TOPIC SPEAKER07:20 PM - 07:30 PM Opening Prof. Humaid Al-Shamsi

CHAIRPERSON: DR. DINA HAMZA │ DR. EMAD HAMADA

09:00 PM - 09:10 PM Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHER randomised trial


09:30 PM - 09:40 PM Analysis of study drug–related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)


09:20 PM - 09:30 PM Pertuzumab/Trastuzumab in Early Stage HER2-positive Breast Cancer: 5-year and Final Analysis of the BERENICE Trial


09:10 PM - 09:20 PM Biomarker analysis from KAITLIN, a randomised phase 3 study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P a�er anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)


09:40 PM - 09:55 PM Decision-making in metastatic HER2+ BC in 2021 Dr. Kevin Punie

09:55 PM - 10:05 PM How low should we go? Treatment for stage I HER2+ disease Dr. Kevin Punie


10:15 PM - 10:45 PM

10:45 PM - 10:50 PM Closing Remarks Prof. Humaid Al-Shamsi

Dr. Aydah Al AwadhiPerspectives on the Subcutaneous Administration of Trastuzumab and Pertuzumab Combination in HER2-positive Breast Cancer


AgendaManaged by

Saturday June 12th | 2021

CHAIRPERSON: DR AYDAH ALAWADHI │ DR DINA HAMZA │ DR SAEED RAFII

09:00 PM - 09:20 PM HR+HER2- Breast Cancer Management Debate Dr. Mohsen Mokhtar & Dr. Hassan Jaafar


09:30 PM - 09:40 PM Clinical Case 1 All



CHAIRPERSON: DR. SAEED RAFII │ DR. METEB AL-FOHEIDI

07:30 PM - 07:40 PM A meta-analysis of the e�icacy of adding immune checkpoint inhibitors to neoadjuvant chemotherapy against triple-negative breast cancer

Dr. Ahmad Awada

07:40 PM - 07:50 PM Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial

Dr. Ahmad Awada

07:50 PM - 08:00 PM Expression Signature of Let-7a, miR-34a and miR-486-5p in Young Triple Negative Breast Cancer Patients Overexpressing PDL1: A Step towards Precision Immuno-oncology

Dr. Hassan Ghazal

08:00 PM - 08:10 PM BRCA1 promoter methylation confers a more favorable prognosis to systemically untreated young triple-negative breast cancer patients than tumor BRCA1 mutation

Dr. Hasssan Ghazal


08:20 PM - 08:30 PM BIO-BREAK

08:30 PM - 09:00 PM Not All CDK 4 & 6 Inhibitors Are Equal

07:00 PM - 07:30 PM Immune checkpoint inhibition in 1L m TNBC

10:00 PM - 10:30 PM Management of HER2+ve Breast Cancer

UAE TIME TOPIC SPEAKER06:50 PM - 07:00 PM Opening Prof. Humaid Al-Shamsi

10:30 PM - 10:40 PM Closing Remarks Prof. Humaid Al-Shamsi

Dr. Hassan Jaafar


Dr. Mark Verrill


BiographyManaged by

Prof. Humaid Al-Shamsi is American and Canadian board certified in Medical Oncology. He completed his medical degree in honors from the University college Cork in Ireland, he completed internal medicine residency and medical oncology fellowship training at McMaster University in Canada.He also completed a fellowship in GI Oncology & Palliative oncology at McMaster University in 2013. He was appointed as an assistant professor in the Department of GI Oncology at MD Anderson Cancer Center, the University of Texas from June 2014 until Dec 2016.He is currently a consultant of oncology and director of Burjeel Cancer Institute Abou Dhabi UAE and holds a professor position at Sharjah University.He is the president of Emirates Oncology Society. Prof. Al-Shamsi has extensive clinical and research experience in solid malignancies and he is a string advocate for palliative care in UAE.

MD(Hon), MRCP(UK), FRCP(C), FACPConsultant of OncologyDirector of Oncology Services - VPS HealthProfessor - University of SharjahEOS President


MDProfessor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Dr. Nuhad Ibrahim

Dr. Nuhad Ibrahim, MD is a practicing Hematologist & Oncologist in Houston, Texas, US. Dr. Ibrahim graduated from University of Baghdad A1-Kindy College of Medicine in 1980 and has been in practice for 38 years. He completed a residency at University of Texas Health Science Center.Dr. Ibrahim also specializes in Internal Medicine an Oncology. He currently practices at MD Anderson Cancer Center. Dr. Ibrahim is board certified in Internal Medicine and Medical Oncology an was honored with Master of American College of Ethical Physicians, American College of Ethical Physicians in 2008 and Award Doctors in America in 2003.

Prof. Dr. med. Peter A. Fasching is Associate Professor of Gynecology and Obstetrics, Translational Medicine, Department Gynecology/Obstetrics, at University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, in Erlangen, Germany. Additionally, Professor Fasching is Head of the Clinical Trials Unit, Department Gynecology/Obstetrics, at University Hospital Erlangen, where he also serves as Head of the Biomaterial Bank and Coordinator of the Breast Cancer Center and Gynecologic Oncology Center. He has received numerous awards, including the Schmidt-Matthiesen Award and the Gunter Bastert Innovation Award of the German Society of Gynecology and Obstetrics, and the Florence Nightingale Award of the German Society of Breast Diseases.Professor Fasching received his medical degree from the Medical School, University of Cologne. His doctoral thesis at the Institute of Pathology, Cologne, was on the topic of PCNA activity in bone marrow before and a�er bone marrow transplantation in patients with chronic myelogenous leukemia. He also served as a Research Fellow in the Department of Hematology/Oncology, UCLA, Los Angeles. He is board certified in Gynecology and Obstetrics.Funded research projects of Professor Fasching include Pharmacogenetics of Breast Cancer, Clinical Data Intelligence, and Machine Learning with Knowledge Graphs.Professor Fasching is widely published in peer-reviewed journals, and he is the author or coauthor of more than 550 publications appearing in journals including Annals of Oncology, Journal of Clinical Oncology, New England Journal of Medicine, and Journal of the National Cancer Institute. He is listed as a “Highly Cited Researcher 2019” (https://hcr.clarivate.com/).

MDAssociate Professor of Gynecology and Obstetrics, Translational Medicine,University Hospital Erlangen, Germany

Dr. Peter Fasching

Dr. Giuseppe Curigliano, MD PhD, is Associate Professor of Medical Oncology at the University of Milano and the Head of the Division of Early Drug Development at the European Institute of Oncology, IRCCS, Italy. He is a clinician and researcher specialising in early drug development for patients with solid tumours with a special commitment to breast cancer. He has been a member of the Italian National Health Council since 2018 and, in 2019, he served as Chair of the Scientific Committee of The Lega Nazionale Lotta ai Tumori. He has served as a Member of the ESMO Breast Cancer Faculty since 2001 and he is currently the Faculty Coordinator. He has also served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Co-Chair in St Gallen 2017 and 2019. He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer, Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee. Dr. Curigliano serves ESMO as the Chair of the Guidelines Committee and is a Council Member. He is also the Chair of the Nomination Committee. He served as the Scientific Chair of the IMPAKT ESMO meeting that was held in Brussels in 2014 and as the Breast Cancer (metastatic) Track Chair of the ESMO 2014 meeting in Madrid. He served as Scientific Co-Chair of the ESMO Breast Cancer Congress in 2019 and 2020.He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.He has contributed to over 390 peer-reviewed publications.

MD, PhDAssociate Professor of Medical Oncology University of Milano, Italy



BiographyManaged by

Prof. Pierfranco Conte is Full Professor of Oncology, Director of the Division of Medical Oncology 2 at the Padua Istituto Oncologico Veneto, Coordinator of the Veneto Oncology Network which includes 26 Medical Oncology Divisions in Veneto Region and Director of the Scientific Directorate and research services of the Istituto Oncologico Veneto. Specializations: Medical Oncology, Clinical Immunology and Hematology. Throughout his career, Prof. Conte has been involved in the development of new regimens for the treatment of solid tumors, with special emphasis on breast and ovarian cancer. He has been Principal Investigator of numerous research projects supported by the National Research Council (CNR), the Italian Association for Cancer Research (AIRC), the Ministry of Health and the Ministry of Education and Research. He is author of more than 411 publications in peer-reviewed journals. Main areas of interest are the biological characterization of breast and ovarian cancer and the development of clinical trials in these disorders.Prof Conte is the recipient of the 2007 Claude Jacquillat Award for Achievement in Clinical Oncology and was awarded the “Stelle della Fenice nel Mondo” prize for scientific excellence in 2014.

MD, Professor of Oncology, Director of the Division of Medical Oncology 2 at the Padua IstitutoOncologico VenetoUniversity of PadovaIstituto Oncologico Veneto, Italy



MD, MSc, FRCP(C)Medical Oncologist at the Juravinski Cancer CentreAssociate Professor and Associate Chair (Education) in the Department of Oncology at McMaster University, Canada

Dr. Bindi Dhesy-Thind is an Associate Professor and Associate Chair (Education) in the Department of Oncology at McMaster University, Hamilton, Ontario, Canada. She is a medical oncologist at the Juravinski Cancer Centre with a clinical and research interest in breast and gastrointestinal malignancies. She holds a MD from Queen’s University and an MSc in Health Research Methodology from McMaster University where she also completed her Residency and Fellowship training. Dr. Dhesy-Thind is a Committee Member for the Program in Evidence Based Care - Cancer Care Ontario, Breast Disease Site and has been a leader in developing internationally endorsed clinical practice guidelines.


BiographyManaged by

Dr. Mark Verrill is Head of the Department of Medical Oncology at the Northern Centre for Cancer Care at the Freeman Hospital, Newcastle upon Tyne and Lead Clinician for Breast Cancer in the Northern Cancer Alliance. He graduated from the University of Cambridge in 1999 before undertaking specialist training in Medical Oncology at the Royal Marsden Hospital and Institute of Cancer Research. Mark was appointed as Cancer Research Campaign Clinical Senior Lecturer in Medical Oncology in Newcastle University in 1999, moving into the NHS in 2007. Mark is an active in clinical research with an extensive breast cancer trial portfolio in NCCC and numerous publications resulting from clinical studies. MD,

Medical Oncologist, Freeman HospitalLead Clinician for Breast Cancer, Northern Cancer Alliance, UK

Dr. Mark Verrill

Since 2005, Dr. Ahmad Awada is Head of the Medical Oncology Clinic. From 2011, Dr Awada was held Associate Head of Medicine Department. He has an important clinical activity in the treatment of solid tumors and particularly breast cancer. Dr. Awada took an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy).

He is membership of several international scientific societies (ASCO, EORTC, ESMO) and Professor of Clinical Medicine at the Université Libre de Bruxelles.

He published 32 book chapters and 316 articles in international publications.

MD, PhD Head of Medical Oncology Clinic at Jules Bordet Cancer Institute Brussels, Belgium

Dr. Ahmad Awada


BiographyManaged by

MDMedical oncologist at the department of General Medical Oncology, University Hospitals Leuven, Belgium

Dr. Kein Punie

Dr. Kevin Punie is a medical oncologist working as a sta� member at the department of General Medical Oncology in the University Hospitals Leuven, Belgium. His main areas of interest are breast cancer and hereditary cancer syndromes. He is deeply involved in clinical cancer research as principal investigator for several phase I-III trials with a focus on triple negative breast cancer. He is currently working on a PhD investigating plasma and tissue single-cell multiomics and their dynamic changes as a response to immune checkpoint inhibitors in early triple negative breast cancer. He is involved in the EORTC Breast Cancer Group, elected board member of the Belgian Society of Medical Oncology and Committee member of ESMO Young Oncologists Committee and ESMO Resilience Task Force.

MDConsultant Medical Oncologist UAE

Dr. Aydah Al Awadhi

Dr. Aydah Al Awadhi graduated from The United Arab Emirates University in Al-Ain and completed residency in Saint Vincent hospital a�iliated with University of Massachusetts in Worcester, MA and recently completed fellowship training in Hematology/Oncology at MD Anderson Cancer Center. While at MD Anderson Cancer Center, Dr Al-Awadhi published number of peer review articles in international journals and presented abstracts mainly in breast cancer presented in US national meetings. She also wrote multiple book chapters. Dr. Al-Awadhi also wrote number of international book chapters in breast cancer.

Prof. Mohsen Mokhtar is director at Kasr El Aini Oncology Unit at Cairo University Kasr El Aini Medical School. He is a Professor Clinical Oncology and he developed syllabus and overall course structure with clinical attachment, as well as supervision of several research programs and thesis.He has more than 50 publications in several regional and international magazines.He is now focusing on clinical trials in Thoracic, Breast, and Gynaecologic malignancies.He is collaborating in several trials both regional and international and he is Scientific coordinator for many regional and international conferencesProf Mohsen is a Speaker at several conferences: In both regional and international conferences: PAN ARAB, EURO-Mediterranean conferences, EASO classes Kasr El Aini School of Oncology.

MDProfessor Clinical Oncology Cairo University, Managing Director of Cairo University Center of Oncology and Nuclear Medicine NEMROCK, EgyptPresident of CANSURVIVE

Prof. Mohsen Mokhtar


BiographyManaged by

Dr Hassan Ghazal is an American board-certified Consultant Medical Oncologist and a Consultant Clinical hematologist o�ering more than 3 decades of clinical experience.Dr Hassan Ghazal, a�er doing his basic medical education in American University of Beirut, moved to US for his residency program in Internal Medicine at Sinai Hospital of Baltimore, MD. In 1992, completing the residency program, Dr Hassan Ghazal joined in George Washington university Medical Center for his fellowship in Medical Oncology and completed the same in 1995. He continued in George Washington University Medical Center for another 2 years and obtained his senior fellowship in bone marrow transplantation in the year 1997. He got his US board certification in Internal Medicine, Medical Oncology and in Hematology in the year 1992, 1995, 1996 respectively.Except his association with CMC for the preceding 3 years, all his clinical practices were in US in various capacities including Director, Kentucky Cancer Clinic and Sta� Oncologist/ Hematologist at Hazard Appalachian Regional Medical Center.Dr Hassan Ghazal is a member of various clinical societies such as American College of Physicians, American Society of Haematology, American Society of Clinical Oncology, European Society of Medical Oncology etc. Dr Hassan Ghazal has got many publications and abstracts in his credit, in peer reviewed journals, and there are many international recognitions and accolades in his name.He has been involved in numerous clinical trials, nearly 100, in the US, serving as Principal Investigator, for over 25 years, and enrolled hundreds of patients in these trials.

MD, American Board-CertifiedConsultant Medical Oncologist & Consultant Clinical HematologistKing's College Hospital, UAE

Dr. Hassan Ghazal

Dr. Dalia Elshourbagy is a Consultant Medical Oncology at Dubai Health Authority since 2009.

Dr. Elshourbagy is an Assistant Professor of Clinical Oncology University Hospital Egypt.

PhD clinical oncologyAssistant professor clinical Oncology Senior Specialist Medical Oncology, Dubai Hospital, UAE

Dr. Dalia Elshourbagy


BiographyManaged by

MDMedical Oncology ConsultantSheikh Khalifa Specialty HospitalRas Al Khaimah, UAE

Dr. Hassan Jaafar

Dr. Hassan Jaafar, is a medical oncology consultant in SKSH. He received his M. B. Ch. B (MD) in 1992, the internal medicine board in 1997, and he passed the Arab board exam in internal medicine, he completed a 3 years of fellowship in hematology- oncology and certified as a medical hematologist oncologist from American university hospital of Beirut in the year 2000.Worked as a medical oncology consultant at Tawam hospital (a�iliated with Johns Hopkins) UAE, from the year 2000 till feb-2018He became an Assistant professor in the department of internal medicine, college of medicine and health sciences of the UAEEU as he lectured in Al-Ain university faculty of medicine between 2008-2018 He moved to Sheikh Khalifa Speciality Hospital (SKSH) operated by Seoul National University Hospital (SNUH) in Ras Alkhaima in March 2018He is the author and co-author of more than 50 peer-reviewed papers and abstracts.He is involved in more than 6 ongoing phase III trials regional and international and he is a member of the GOG (gulf oncology group) that conducted 2 phase II trialsHe is member in many societies (UAE Oncology and radiation therapy association, Emirate of Gyn-oncology group, Lebanese hematology and oncology association, ESMO European society of medical oncology, ASCO American society of clinical oncology, and Member in the NCCN MENA subcommittee for HCC, Lung ca) Elected as a Member of the Scientific and Education Committee of the Arab Collaborative Hematology and Oncology Group (ACHOG), GIST working Group, member of the Africa Middle East Cancer Research Intergroup (AMCI)

Dr. Maroun El Khoury American Board Certified in Oncology, Hematology and Internal MedicineDr. El Khoury is Director of Cancer Care Center at American Hospital DubaiHe is also President of Medical Sta� at American Hospital.Dr. El Khoury is Chairman of Scientific Committee at Emirates Oncology Society

MDConsultant Hematologist/Oncologist at American Hospital, UAEChairman of Scientific Committee EOS



BiographyManaged by


Managed by

The Emirates Oncology Society would like to express its gratitude

to the following stakeholders for their unconditional support to this meeting.

Platinum Sponsors

Gold Sponsors

Sponsors

Booklet Esmo - Emirates Oncology Society

Documents

Transcript of Booklet Esmo - Emirates Oncology Society